Journal
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 29, Issue 9, Pages 2401-2408Publisher
AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2018040365
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [K23 HL131023, K24 DK 110427]
- NIDDK [000182, UL1TR000124, P30AG021684]
Ask authors/readers for more resources
Background During intensive BP lowering, acute declines in renal function are common, thought to be hemodynamic, and potentially reversible. We previously showed that acute declines in renal function 20% during intensive BP lowering were associated with higher risk of ESRD. Here, we determined whether acute declines in renal function during intensive BP lowering were associated with mortality risk among 1660 participants of the African American Study of Kidney Disease and Hypertension and the Modification of Diet in Renal Disease Trial. Methods We used Cox models to examine the association between percentage decline in eGFR (<5%, 5% to <20%, or 20%) between randomization and months 3-4 of the trials (period of therapy intensification) and death. Results In adjusted analyses, compared with a <5% eGFR decline in the usual BP arm (reference), a 5% to <20% eGFR decline in the intensive BP arm was associated with a survival benefit (hazard ratio [HR], 0.77; 95% confidence interval [95% CI], 0.62 to 0.96), but a 5% to <20% eGFR decline in the usual BP arm was not (HR, 1.01; 95% CI, 0.81 to 1.26; P<0.05 for the interaction between intensive and usual BP arms for mortality risk). A 20% eGFR decline was not associated with risk of death in the intensive BP arm (HR, 1.18; 95% CI, 0.86 to 1.62), but it was associated with a higher risk of death in the usual BP arm (HR, 1.40; 95% CI, 1.04 to 1.89) compared with the reference group. Conclusions Intensive BP lowering was associated with a mortality benefit only if declines in eGFR were <20%.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available